Influenza A Virus, H7N9 Subtype Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Influenza A Virus, H7N9 Subtype Infections – Pipeline Review, H2 2016’, provides an overview of the Influenza A Virus, H7N9 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H7N9 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H7N9 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

EpiVax Inc

Fab’entech

Genentech Inc

GlaxoSmithKline Plc

Medigen Vaccine Biologics Corp

NanoViricides Inc

Visterra Inc

Vivaldi Biosciences Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Influenza A Virus, H7N9 Subtype Infections Overview 7

Therapeutics Development 8

Pipeline Products for Influenza A Virus, H7N9 Subtype Infections - Overview 8

Pipeline Products for Influenza A Virus, H7N9 Subtype Infections - Comparative Analysis 9

Influenza A Virus, H7N9 Subtype Infections - Therapeutics under Development by Companies 10

Influenza A Virus, H7N9 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 11

Influenza A Virus, H7N9 Subtype Infections - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Influenza A Virus, H7N9 Subtype Infections - Products under Development by Companies 14

Influenza A Virus, H7N9 Subtype Infections - Products under Investigation by Universities/Institutes 15

Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development 16

EpiVax Inc 16

Fab’entech 17

Genentech Inc 18

GlaxoSmithKline Plc 19

Medigen Vaccine Biologics Corp 20

NanoViricides Inc 21

Visterra Inc 22

Vivaldi Biosciences Inc 23

Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AT-501 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

FBF-002 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GSK-3206640A - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GSK-3206641A - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

influenza [strain A/H7N9] vaccine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

influenza [strain A/H7N9] vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Monoclonal Antibody to Inhibit Hemagglutinin for Influenzavirus A Infections - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

NVINF-1 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NVINF-2 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

VIS-410 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Influenza A Virus, H7N9 Subtype Infections – Pipeline by EpiVax Inc, H2 2016 16

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Fab’entech, H2 2016 17

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Genentech Inc, H2 2016 18

Influenza A Virus, H7N9 Subtype Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 19

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Medigen Vaccine Biologics Corp, H2 2016 20

Influenza A Virus, H7N9 Subtype Infections – Pipeline by NanoViricides Inc, H2 2016 21

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Visterra Inc, H2 2016 22

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Vivaldi Biosciences Inc, H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports